ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Rochester, MN, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Rochester, Minnesota, United States and 51 other locations

Locations recently updated

single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...

Enrolling
Leukemia, Myeloid
Drug: CC-96191

Phase 1

Celgene
Celgene

Rochester, Minnesota, United States and 13 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...

Active, not recruiting
Acute Myelogenous Leukemia
Leukemia, Acute Myeloid
Drug: Iomab-B
Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Rochester, Minnesota, United States and 23 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Enrolling
Acute Mixed-Phenotype Leukemia
Acute Lymphoblastic Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

Rochester, Minnesota, United States and 22 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Rochester, Minnesota, United States and 43 other locations

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...

Active, not recruiting
Acute Myeloid Leukemia
Drug: IMGN632
Drug: Venetoclax

Phase 1, Phase 2

AbbVie
AbbVie

Rochester, Minnesota, United States and 30 other locations

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine...

Enrolling
Hairy Cell Leukemia
Drug: Cladribine
Drug: Vemurafenib

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Rochester, Minnesota, United States and 9 other locations

of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS).The ph...

Enrolling
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Drug: CTX-712

Phase 1, Phase 2

Chordia Therapeutics

Rochester, Minnesota, United States and 3 other locations

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and...

Active, not recruiting
Refractory Chronic Lymphocytic Leukemia
Relapsed Chronic Lymphocytic Leukemia
Drug: DTRM-555

Phase 2

Zhejiang DTRM Biopharma

Rochester, Minnesota, United States and 7 other locations

Locations recently updated

with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when g...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Rochester, Minnesota, United States and 164 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems